With an initial fundraising target of £100m and a robust starting portfolio of seven companies, Spex Capital will identify, support, and invest in early-stage digital health companies, allowing them to commercialise and scale within the NHS and other healthcare delivery systems on a global scale. The firm will invest in early stage and series A / B companies, offering tickets up to £5,000,000. 

Success at its core

Spex Capital kicks off with a strong team of twelve in place, made up of five investment team members and seven senior advisors. The team of senior advisors has been carefully chosen on the calibre of their backgrounds and complementary skills in the sector.

Claudio D’Angelo has personally made nine investments in seven target companies which now form Spex Capital’s current portfolio. The majority of these technologies have proven incredibly resilient to the current pandemic environment, have gained market share and are accelerating fund raising for further technological and geographical expansion.

A unique model

Based in London and leveraging its global reach in the sector, Spex Capital will be unique in its genre for the international proposition it offers to health-tech entrepreneurs and investors. Ahead of launch, the firm has already established an ecosystem via partnerships and relationships with accelerators and incubators, universities, hospitals, embassies, chambers of commerce, trade bodies, payors and healthcare systems across all continents to source the highest quality technologies worldwide.

Through its central hub in London and thanks to its ongoing relationship with MedCity, Spex Capital benefits from connections to the NHS in England and several other stakeholders in this vertical.

Claudio D’Angelo, Co-founder and Managing Director of Spex Capital, commented: “Spex, from specere, latin verb for 'to look at’, defines who we are. As thorough observers, we analyse potential investee companies scrupulously, carrying out a detailed due diligence in order to efficiently select and invest in them. Following my experience with Ryse Asset Management, I decided to launch a more ambitious venture both in terms of scale and geographical focus. 

"Many innovative ventures in the digital health and med-tech sector don't get access to the appropriate opportunities in their early stages due to lack of funds and investors tending to favour business models with a longer track record. There is however, an incredible pool of talent with unexpressed potential. This is where Spex comes in. 

"Specialised in advancing disruptive early-stage ventures, our goal is to deliver breakthroughs in healthcare systems globally. Thank you MedCity for the support and thank you also to the incredible team that has chosen to join me in this exciting journey”.